#2026-guidance

#2026-guidance

BTIG rates FTAI a Buy, raising its target from $335 to $340. The firm acknowledges FTAI missed Q4 EBITDA relative to consensus but argues the 2026 setup remains attractive.

Kraft Heinz Co (NASDAQ: KHC) delivered mixed fourth-quarter results on February 11, 2026, beating earnings expectations while missing on revenue. However, the bigger story was CEO Steve Cahillane's decision to halt the planned separation and commit $600 million to a turnaround effort. Shares fell roughly 7% in premarket trading as investors digested the strategic pivot and weak guidance. Q4 Results: EPS Beat, Revenue Miss Kraft Heinz reported adjusted EPS of $0.67, topping consensus of $0.62 by 8.1%. However, revenue of $6.35 billion fell short of $6.44 billion expectations, a 1.4% miss. Organic sales declined 4.2% year-over-year, driven by volume and mix headwinds of 4.7 percentage points.

T-Mobile's Q4 results reflected strong operational momentum offset by workforce restructuring costs. Service revenue climbed 10% YoY to $18.7 billion, driven by postpaid service revenue growth of 13.9%. Operating cash flow surged 20% to $6.65 billion, while adjusted free cash flow reached $4.2 billion. The earnings miss stemmed from $390 million in severance costs ($293 million after-tax) tied to workforce transformation initiatives. Without this charge, operational performance remained robust, with full-year 2025 core adjusted EBITDA hitting $33.9 billion.

Bristol Myers' Growth Portfolio surged 16% to $7.4 billion in Q4, demonstrating the company's successful product diversification strategy. Key contributors included Opdivo at $2.69 billion (+9%), Eliquis at $3.45 billion (+8%), and standout performers Breyanzi at $392 million (+49%) and Camzyos at $353 million (+59%). However, the Legacy Portfolio declined 15% to $5.1 billion as generic competition intensified. Revlimid plummeted 55%, while Sprycel dropped 60%, reflecting the patent cliff challenges facing the company.